Vertex Pharmaceuticals Incorporated (LON:0QZU)
421.74
+0.41 (0.10%)
At close: Nov 20, 2025
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $3.08B USD in the quarter ending September 30, 2025, with 10.99% growth. This brings the company's revenue in the last twelve months to $11.72B, up 10.33% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.72B
Revenue Growth
+10.33%
P/S Ratio
9.49
Revenue / Employee
$1.92M
Employees
6,100
Market Cap
82.73B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
| Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
| Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
| Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
| Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Vertex Pharmaceuticals News
- 18 hours ago - Noteworthy ETF Outflows: IWF, VRTX, BX, MCK - Nasdaq
- 2 days ago - Insider Sell: Atkinson Edward Morrow III Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
- 2 days ago - Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3 - Business Wire
- 3 days ago - Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Nasdaq
- 3 days ago - Columbia Contrarian Core Fund Q3 2025 Performance Review - Seeking Alpha
- 4 days ago - 3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List - Seeking Alpha
- 4 days ago - Is Vertex Pharmaceuticals Inc Gaining or Losing Market Support? - Benzinga
- 5 days ago - PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors - Seeking Alpha